PF-05230907
Phase 1Terminated 0 watching 0 views this week💤 Quiet
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Intracerebral Hemorrhage
Conditions
Intracerebral Hemorrhage
Trial Timeline
Nov 1, 2016 → Jan 1, 2018
NCT ID
NCT02687191About PF-05230907
PF-05230907 is a phase 1 stage product being developed by Pfizer for Intracerebral Hemorrhage. The current trial status is terminated. This product is registered under clinical trial identifier NCT02687191. Target conditions include Intracerebral Hemorrhage.
Hype Score Breakdown
Clinical
10
Activity
5
Company
9
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02687191 | Phase 1 | Terminated |
Competing Products
6 competing products in Intracerebral Hemorrhage
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Edaravone Dexborneol + Placebo | Sun Pharmaceutical | Phase 2 | 52 |
| NXY-059 | AstraZeneca | Phase 2 | 52 |
| Recombinant Factor VIIa + Biological/Vaccine: Placebo | Novo Nordisk | Phase 3 | 76 |
| Recombinant Activated Factor VII (rFVIIa) + Placebo | Novo Nordisk | Phase 3 | 76 |
| CN-105 | Tiantan Bio | Phase 2 | 49 |
| Albumin + Placebo | Baxter | Phase 2 | 49 |